From: Evaluation of new and old biomarkers in dogs with degenerative mitral valve disease
Investigation | Cut-off (pmol/L) | Sensitivity% (95% CI) | Specificity% (95% CI) | AUC (95% CI) | p-value |
---|---|---|---|---|---|
Stage C compared with controls | |||||
  Baseline |  > 1005 | 85.71 (60.06–97.46) | 89.47 (68.61–98.13) | 0.87 (0.7–1) | 0.0003 |
  Follow-up |  > 821 | 100 (60.97–100) | 80 (54.81–92.95) | 0.94 (0.85–1) | 0.0018 |
Stage C compared with stage B1 | |||||
  Baseline |  > 1005 | 85.71 (60.06–97.46) | 80.49 (65.99–89.77) | 0.85 (0.69–1) | 0.0001 |
  Follow-up |  > 883 | 100 (60.97–100) | 75.76 (58.98–87.17) | 0.93 (0.85–2) | 0.0008 |
Stage C compared with stage B2 | |||||
  Baseline |  > 978.5 | 85.71 (60.06–97.46) | 66.67 (35.42–87.94) | 0.8 (0.62–0.98) | 0.0167 |
  Follow-up |  > 1103 | 83.33 (43.65–99.25) | 58.33 (31.95–80.67) | 0.76 (0.53–0.99) | NS |